Literature DB >> 16598307

Aberrant gene promoter methylation marking disease progression in multiple myeloma.

C-S Chim, R Liang, M-H Leung, S-F Yip, Y-L Kwong.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16598307     DOI： 10.1038/sj.leu.2404205

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.

Authors:  M Ben Dhiab; S Ziadi; F Ksiaa; T Louhichi; R Ben Gacem; A Ben Zineb; K Amara; M Hachana; Mounir Trimeche
Journal:  Tumour Biol       Date:  2014-11-15

2.  Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission.

Authors:  Déborah Martínez-Baños; Beatríz Sánchez-Hernández; Guadalupe Jiménez; Georgina Barrera-Lumbreras; Olga Barrales-Benítez
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447

3.  Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Authors:  Kwan Yeung Wong; Chi Chiu So; Florence Loong; Lap Ping Chung; William Wai Lung Lam; Raymond Liang; George Kam Hop Li; Dong-Yan Jin; Chor Sang Chim
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

Review 4.  The role of epigenetics in the biology of multiple myeloma.

Authors:  K Dimopoulos; P Gimsing; K Grønbæk
Journal:  Blood Cancer J       Date:  2014-05-02       Impact factor: 11.037

5.  The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Authors:  Mohammad Alzrigat; Alba Atienza Párraga; Muntasir Mamun Majumder; Anqi Ma; Jian Jin; Anders Österborg; Hareth Nahi; Kenneth Nilsson; Caroline A Heckman; Fredrik Öberg; Antonia Kalushkova; Helena Jernberg-Wiklund
Journal:  Oncotarget       Date:  2017-10-20

6.  Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses.

Authors:  Qiumei Yao; Gareth J Morgan; Chor Sang Chim
Journal:  Clin Epigenetics       Date:  2018-12-20       Impact factor: 6.551

7.  Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.

Authors:  Xi Yun Zhang; Deepa Rajagopalan; Tae-Hoon Chung; Lissa Hooi; Tan Boon Toh; Johann Shane Tian; Masturah Bte Mohd Abdul Rashid; Noor Rashidha Bte Meera Sahib; Mengjie Gu; Jhin Jieh Lim; Wilson Wang; Wee Joo Chng; Sudhakar Jha; Edward Kai-Hua Chow
Journal:  Exp Hematol Oncol       Date:  2020-05-22

Review 8.  Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.

Authors:  Amro M Soliman; Teoh Seong Lin; Pasuk Mahakkanukrauh; Srijit Das
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

9.  Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Authors:  Larissa Haertle; Santiago Barrio; Umair Munawar; Seungbin Han; Xiang Zhou; Cornelia Vogt; Rafael Alonso Fernández; Max Bittrich; Yanira Ruiz-Heredia; Matteo Da Viá; Josip Zovko; Andoni Garitano-Trojaola; Niccolò Bolli; Anna Ruckdeschel; Thorsten Stühmer; Manik Chatterjee; Miriam Kull; Jan Krönke; Xabier Agirre; Jose I Martin-Subero; Peter Raab; Hermann Einsele; Leo Rasche; Joaquin Martinez-Lopez; Thomas Haaf; K Martin Kortüm
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.